Charles River Laboratories Deep Value Investment Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  Conclusion: CRL's ceiling is not low, but it is more about going deeper, expanding, and taking share within the existing non-clinical R&D outsourcing pie than about having already created a new market. New methods such as NAMs, AI, in vitro systems, and organ-on-chip may redraw industry boundaries, but for CRL they remain an opportunity and a risk tied to upgrading or replacing the old market. They should not be directly elevated into a narrative of exclusive control over a new market.

  In terms of scale, the company's own framing shows that it addresses an approximately $25 billion serviceable market and has approximately $4 billion of LTM revenue. The local report puts 2025 revenue at $4.015 billion, of which DSA was $2.403 billion, or 59.8%. This shows CRL still has room to grow: higher customer outsourcing rates, greater wallet share, bioanalysis, in vitro services, NAMs, manufacturing quality control, and regional expansion can all add incremental revenue. But this is not a blank-sheet market, because the same company materials also show CRL has approximately 40% share in research models and approximately 30% share in outsourced safety assessment. In other words, it is already a major player in its core lanes. Future growth will come more from penetration, share, pricing, M&A, and technological transition than from opening a demand pool from zero that no one has addressed before.

  Near-term operating data also warns against confusing the market ceiling with current growth. In Q1 2026, the company disclosed that total organic revenue declined 1.5%, RMS organic revenue declined 5.5%, DSA organic revenue declined 1.4%, and full-year organic revenue guidance remained down 1.5% to 0.5%. So the market ceiling can support a long-term recovery and a mid-single-digit to high-single-digit growth assumption, but there is still no evidence of explosive demand opening up.

  The real potential ceiling changer is a shift in the regulatory and technology paradigm. The FDA has clearly promoted NAMs, including in vitro human-based systems, computational models, and other methods to reduce or replace animal testing. If CRL can move from a traditional animal/NHP and safety assessment operator into a platform for new-method validation, regulatory interpretation, and non-clinical integration, the quality of its serviceable market could improve. But if NAMs primarily erode the profit pool of traditional animal testing and CRL merely replaces lost revenue passively, the ceiling would instead be compressed. My view is that CRL has a large enough existing market to cultivate, but the evidence is still insufficient to label it a creator of an entirely new market.

  Jun 6, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?2/10

  A

  Conclusion: In the base case, I do not think CRL's revenue can at least double over the next five years. Starting from 2025 revenue of approximately $4.015 billion, doubling in five years would mean reaching approximately $8 billion, requiring about 14.9% CAGR. That is far from the company's current cadence: the report gives historical 2020-2025 revenue CAGR of about 6%-7%, while in Q1 2026 the company still disclosed full-year organic revenue guidance of -1.5% to -0.5%, with Q1 organic revenue itself down 1.5%. If 2026 first posts a small negative growth year, the remaining four years would need roughly 19% annual growth to catch up to a doubling. That no longer looks like natural operating recovery; it would require large-scale M&A or a breakout in new businesses.

  On growth drivers, the most likely main axis remains volume, not price. CRL's core revenue comes from DSA and RMS, with DSA accounting for about 59.8% of total revenue in 2025. These safety assessment, non-clinical development, and research model businesses are essentially pulled by customer project volume, study starts, outsourcing penetration, and capacity utilization. The problem is that Q1 2026 RMS organic revenue declined 5.5% and DSA organic revenue declined 1.4%, which means there is still no project-volume recovery strong enough to support 15% compound growth.

  Price can contribute, but it is not enough to be the main reason for a doubling. The report notes that safety assessment had relatively strong price increases in 2022-2023, but in 2025-2026 the company faces cautious customers, study starts costs, large-model/NHP sourcing costs, site consolidation, and restructuring pressure. In other words, CRL has some pricing power, but it is not an asset-light software company that can double revenue over five consecutive years by raising prices. When customer R&D budgets are under pressure, excessive price increases could also damage volume.

  The only path that can make a “five-year doubling” work is new businesses/new paradigms plus M&A: for example, upgrading the traditional animal testing platform into NAMs, in vitro, AI-assisted toxicology, regulatory validation, and non-clinical integration. But this line still looks more like an option than a second curve already proven by financial data. The FDA is promoting NAMs, AI models, organ chips, and other methods to reduce or replace animal testing, which could give CRL new service opportunities and could also erode its traditional animal/NHP value chain. In addition, the company divested CDMO and Cell Solutions in 2026, making the portfolio more focused but the near-term revenue base smaller, which raises the difficulty of doubling.

  So my judgment is: revenue doubling over the next five years is not the base case to underwrite; a more reasonable expectation is that core DSA/RMS recover from negative growth to low-single-digit or mid-single-digit organic growth, with small contributions from price, efficiency, and bolt-on M&A. If CRL can prove over the next two or three years that NAMs/new non-clinical methods are not substitution pressure, but a new revenue pool that it validates, integrates, and delivers at scale, then we can reopen the discussion about above-10% compound growth. With today's data, there is not enough evidence to describe it as a five-year revenue-doubling growth stock.

  Jun 6, 2026
• QFive years from now, what will take over as the next growth engine? Does this “second curve” exist today?3/10

  A

  Conclusion: CRL's “second curve” has an outline today, but it is not yet a financially validated second curve. The most likely direction to take over five years from now is upgrading traditional DSA from an “animal/NHP safety assessment operator” into a “regulated non-clinical methods integration platform”: NAMs, AI, in vitro models, digital pathology, virtual control groups, and regulatory validation capability sold together to customers. The issue is that this curve currently looks more like a defensive transformation, and it has not yet proven that it can offset the substitution risk facing the traditional animal/NHP revenue pool.

  In the report, CRL had 2025 revenue of $4.015 billion, of which DSA was $2.403 billion, or about 59.8%, still the core revenue and profit anchor; RMS was $846 million and Manufacturing was $766 million, neither of which looks like a standalone engine ready to take over. The start of 2026 also did not show that a “new curve is already pulling the company”: Q1 total organic revenue declined 1.5%, RMS organic revenue declined 5.5%, DSA organic revenue declined 1.4%, and full-year organic revenue guidance remained down 1.5% to 0.5%. This shows the current main line is still repair and restructuring, not accelerated expansion.

  NAMs/AI/in vitro models are the only candidate that looks like a real “second curve.” The external regulatory direction is indeed on this side: the FDA defines NAMs as including in vitro human-based systems, in silico modeling, and other methods that can reduce or replace animal use, and its roadmap also proposes gradually moving animal studies from a default to an exception in some preclinical safety/toxicity testing. CRL itself is already promoting NAMs, in vitro, in silico, Logica, virtual control groups, and AI digital pathology; for example, the company says its AI digital pathology workflow can shorten pathology timelines and support reduced animal use when scientifically appropriate. But the investment question is: will these capabilities become high-margin, scalable new revenue, or are they mainly there to protect the existing DSA business from substitution? Public disclosures currently do not provide standalone revenue, growth rate, and margin for NAMs/AI/in vitro models, so we can only say that “products and capabilities exist,” not that “the second curve is established.”

  NHP vertical integration looks more defensive than like a second curve. In January 2026, the company acquired K.F. Cambodia's NHP assets for approximately $510 million, aiming to vertically integrate a critical supply chain into DSA/RMS. This can reduce supply interruptions, cost volatility, and delivery risk, and may improve the reliability of the safety assessment business in the short term; but it also commits more capital to the NHP chain, which faces long-term erosion from NAMs. Therefore, it is more like a guardrail that stabilizes the first curve, not a new growth engine that takes over five years from now.

  Portfolio refocusing is also not itself a second curve. In May 2026, the company completed the divestiture of CDMO and Cell Solutions and said it would refocus the portfolio on core capabilities such as regulated drug development testing. This helps reduce lower-quality assets, repair margins, and improve returns on capital, but in essence it is “cleaning up the first curve,” not creating a new market. The real validation signals should be: DSA organic growth turns positive again, NAMs/digital/in vitro-related services form a material disclosed revenue share, and the company's capital dependence on the NHP supply chain declines. If those appear, CRL could move from a traditional non-clinical CRO into a non-clinical methods platform under the new regulatory paradigm. Today, it still has option value, but it is not yet the base case.

  Jun 6, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  Conclusion: CRL's core competitive advantage is an execution barrier built from “scaled, regulated non-clinical R&D infrastructure + GLP compliance record + customer trust + research model/site network,” not network effects. Over the next three to five years, I lean toward judging this moat as stable at the core, with a modest risk of narrowing overall: traditional DSA, research models, and safety assessment still have barriers, but substitution pressure from NAMs on the animal/NHP testing value chain is rising.

  CRL is not an ordinary outsourced lab company. The company had 2025 revenue of about $4.015 billion, with DSA revenue of about $2.403 billion, or 59.8% of total revenue; in its annual report, the company calls itself the world's largest provider of outsourced drug discovery, non-clinical development, and regulated safety testing services. The significance of this scale is that customers are not buying a single experiment, but an infrastructure set that can span discovery, safety assessment, research models, quality control, and regulatory filing support. The company also has more than 120 sites across more than 20 countries, giving it economies of scope in capacity scheduling, model supply, cross-region services, and large-customer coverage.

  The deeper barrier is regulation and trust. Non-clinical safety assessment is not a “choose whoever is cheapest” service. GLP data, animal welfare, data integrity, audit history, and report acceptability all affect customers' drug development timelines. CRL discloses that its safety assessment facilities comply, when required, with FDA, EMA, OECD, and other GLP/animal welfare requirements, and are subject to regulatory agency, customer quality assurance, and internal quality audits. Once a candidate drug, toxicology plan, research model, and historical data chain have been started at CRL, switching suppliers midway brings risks around method rebuilding, data consistency, time delays, and regulatory document continuity. That is the switching cost. In 2025, no single customer accounted for more than 4% of total revenue, and no single customer accounted for more than 8% of any segment revenue, showing that it is not relying on a few customer locks, but on a platform position built from broad customer trust.

  Sites and research model infrastructure are also part of the moat. RMS, DSA, and the NHP supply chain all require long-term capital, personnel training, animal facilities, health monitoring, quarantine, transport, and compliance systems. A new entrant cannot fully replicate this in one or two years simply by spending money. The 2026 acquisition of a Cambodian NHP supplier internalizes critical supply and strengthens control over large-model resources; at the same time, it also shows that this moat carries the costs of heavy assets, heavy compliance, and heavy supply chain exposure. It is not asset-light software-style compounding.

  But the weaknesses are also clear: CRL's network effects are weak, and customer A's usage does not materially raise the value for customer B. It has project experience and methodological accumulation, but it is not yet an irreplaceable proprietary data flywheel. More importantly, the FDA is promoting NAMs, covering in vitro human-based systems, in silico modeling, organ-on-chip, AI, and other methods, with the goal of reducing, replacing, or refining animal testing. The FDA roadmap even proposes that, over the long term, animal testing could move from a default requirement to an exceptional circumstance. This is a double-edged sword for CRL: if it becomes the validator, integrator, and regulated execution platform for NAMs, the moat can change form; if it still mainly relies on traditional animal/NHP testing, the old moat will be weakened.

  So my judgment is: CRL's moat is real but not automatically widening. Over the next three to five years, scale, GLP, customer trust, and research model infrastructure can still protect core DSA/RMS; but Q1 2026 RMS organic revenue of -5.5%, DSA organic revenue of -1.4%, and full-year organic revenue guidance of -1.5% to -0.5% show that near-term demand and margins are not strong. Unless management can fold NAMs, in vitro models, AI toxicology, and regulatory validation capabilities into its own platform, this moat is more likely to be “stable at the core, narrower at the edges” than clearly widening.

  Jun 6, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?4/10

  A

  Conclusion: CRL has the DNA to reinvent itself, but it is not a nimble growth company that proactively disrupts itself; it is more like a mature platform forced by bad news to shrink, refocus, and correct capital allocation. The good side is that management has not clung to every old asset, and has already divested lower-quality businesses, rebuilt control over the NHP supply chain, and established a NAMs governance structure. The bad side is that corrections often come at a high cost, and shareholders have already paid through impairments, disposal losses, and a more complex balance sheet.

  The clearest evidence is portfolio restructuring. On May 6, 2026, the company completed the divestiture of the CDMO and Cell Solutions businesses, and expected to complete the sale of certain European Discovery Services sites in May 2026. An earlier 8-K showed that CDMO/Cell Solutions were sold to GI Partners mainly through future contingent performance payments, while the European Discovery Services assets were sold to IQVIA for approximately $145 million in cash, involving about $144 million of 2025 revenue, with the company retaining about 40% of Discovery Services revenue. This is not an optimization that adds shine to an already good story. It is an admission that part of the expansion did not create enough synergy and moat, followed by pulling capital and management attention back to regulated drug development testing, DSA, RMS, and more core manufacturing quality control capabilities.

  The handling of the NHP supply chain shows the same two-sided nature. CRL did not simply exit the traditional in vivo/NHP model. In January 2026, it acquired the NHP assets of K.F. (Cambodia) for $510 million, internalizing key supply risk. The annual report also disclosed that in 2024, inventory related to the Cambodia NHP matter had been written down to zero, and that after related government investigations were resolved in 2025, some NHPs became usable. This action shows that the company is willing to face supply chain bad news and strengthen control, but it also shows that “fixing mistakes” is not free: it brings more regulatory, geopolitical, compliance, and asset-specific risk onto the balance sheet.

  The real determinant of whether it can reinvent itself is NAMs. The FDA is promoting NAMs, including human-based in vitro systems, computational models, and other NAMs to reduce or replace animal testing, which directly hits CRL's traditional animal model and NHP value chain. The company is not completely passive: in 2025, it combined the Responsible Animal Use Committee and the Science and Technology Committee into the New Approach Methodologies and Science Committee, and established a cross-functional Scientific Advisory Board to advance NAMs. This is a reasonable transformation path: if CRL can upgrade from an “animal testing operator” into a “traditional non-clinical + NAMs validation + regulatory integration platform,” its moat may still continue. If it treats NAMs as marketing while revenue and profit remain highly dependent on traditional animal/NHP supply, the long-term moat will narrow.

  On its attitude toward mistakes and bad news, I would rate it “moderately positive, but costly.” The report has already pointed out that there was $215 million of goodwill impairment in 2024, and that in 2025 there were further large intangible asset/goodwill impairments related to Cell Solutions, CDMO Gene Therapy, and Biologics Solutions; in Q1 2026, the company also recognized a $118 million held-for-sale asset loss related to the CDMO/Cell Solutions divestiture. This shows the company has not kept bad assets on the books forever and has not completely avoided confronting the problem; but it also reminds investors that CRL's mistakes are usually not small experiments. They are the outcome of years of M&A and expansion, surfacing all at once through the income statement, impairments, and disposal discounts. From a Baillie Gifford perspective, this company “can change,” but it has not yet proven that it can “change at low cost and ahead of time.”

  Jun 6, 2026
• QDoes management, especially the founder, have a long-term perspective and deep alignment with the company? Is it willing to sacrifice current profits for the next five to ten years?4/10

  A

  Conclusion: CRL's management alignment is adequate, but it is not the “founder-major shareholder + willingness to sacrifice ten years of profit for huge upside” type that the Baillie Gifford framework most prefers. The company looks more like a mature professional-manager governance system: the long-time leader left behind real capabilities and a cash-flow platform, and the new CEO also has equity, ownership guidelines, and clawback constraints; but share ownership is not a controlling bond, incentives still lean toward 3-year TSR, non-GAAP EPS, and capital discipline, and past M&A impairments show that capital allocation has not been consistently excellent.

  Start with people and ownership. The 2026 proxy disclosed that James Foster stepped down as CEO/chairman on May 5, 2026, and Birgit Girshick took over as CEO; as of March 16, 2026, Foster held 361,012 shares, Girshick held 76,303 shares, and current executives and directors together owned about 1.3%. This is not “no skin in the game,” and at a share price of about $180, the absolute dollar amount is meaningful. But it is also not a founder-controlled company, so investors cannot expect management to naturally put the stock price ten years from now ahead of the current income statement in the way a major founder-family shareholder might.

  The governance design is somewhat better than the average company. The company requires the CEO to hold shares equal to 6 times base salary and EVPs to hold 3 times, and only vested RSUs/PSUs and other full-value shares count toward the measure; it also has clawback provisions and bans hedging and pledging. In 2025, about 80% of the CEO's long-term incentive was PSU-based and tied to non-GAAP EPS and relative TSR, which at least constrains management more than a pure cash bonus would and discourages a one-quarter focus. But from a Baillie Gifford perspective, this is still not a 5-10-year founder objective function: non-GAAP EPS and 3-year TSR can encourage margin repair, buybacks, and portfolio optimization, but may not encourage large early investment for a new paradigm or tolerance of years of profit sacrifice.

  The capital allocation evidence is mixed. On the positive side, the company is acknowledging past portfolio problems and narrowing the front: after Q1 2026, CDMO and Cell Solutions were sold to GI Partners, and the company planned to sell certain European Discovery Services sites, consistent with the report's repair path of returning to the core DSA/RMS platform after divestitures; the company also repurchased 1.1 million shares for $200 million in Q1, with $800 million of authorization remaining, showing that management believes cash flow and valuation provide support. On the negative side, the 2024-2025 impairments and divestitures in Biologics, CDMO/Cell Solutions, and related areas, especially the additional $165 million goodwill impairment in Biologics Solutions in 2025, show that not every prior acquisition-led expansion created long-term value.

  Elliott's involvement also cuts both ways. The 2026 proxy shows that the company reached a cooperation agreement with Elliott and added Elliott's Steven Barg and others to the director candidate/director slate; this will strengthen capital allocation discipline and push the company to deal with low-return assets, improve buyback efficiency, and focus the portfolio. But this type of activist pressure typically emphasizes value realization and better returns more than unconditional support for management to sacrifice current profits for a technology migration ten years out.

  So my judgment is: management is “basically credible, partly aligned, and supported by adequate governance,” but it still cannot receive a high score. If the question is “will they tolerate short-term profit pressure to rebuild the business for CRL five to ten years from now?” the answer is: they will do some of it, especially divesting low-quality assets, integrating NHP supply, and focusing on regulated drug development testing; but the current evidence looks more like repair and discipline in a mature platform than aggressive reinvention driven by founder-style long-termism. Under the Baillie Gifford framework, this item is roughly moderately positive, not a strong bonus point in a ten-year fivefold story.

  Jun 6, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?5/10

  A

  Conclusion: Customers would clearly miss CRL, but not to the point of an industry shutdown; it is critical infrastructure in highly regulated non-clinical R&D, not the only infrastructure. In GLP safety assessment, research models, NHP/large-animal studies, cross-site execution, and regulatory reporting, the cost of switching suppliers is not just running a new tender. It means method transfer, historical data consistency, audit trust, and IND timeline risk. CRL calls itself the world's largest outsourced drug discovery, non-clinical development, and regulated safety assessment provider; in 2025, DSA accounted for 59.8% of revenue, and the company had 120+ sites across 20+ countries. At the same time, no single customer accounted for more than 4% of total revenue in 2025, showing dispersed demand and a real customer base.

  But “being missed” is not the same as “irreplaceable.” Large pharma companies can shift to other CROs, internal labs, or split work across multiple suppliers. What is truly hard to replace is ongoing regulated research, complex models, NHP supply, quality systems, and continuity in regulatory filings. So I would rate customer indispensability as medium-high: painful in core DSA and some RMS/NHP settings, but not so strong as to be irreplaceable in ordinary project-based services and peripheral businesses.

  Social and regulatory sustainability is where this company most needs a discount. CRL's historical advantages come from animal models, in vivo biology, NHP supply, and regulated safety testing. These still have scientific demand, but social license and regulatory direction are changing. The company's own 2025 10-K also acknowledges that if animal research is replaced or eliminated, it could have a material adverse effect on the business. At the same time, the NHP supply chain was once involved in DOJ/USFWS and SEC investigations; although the DOJ/USFWS investigations were closed in 2025 and the SEC also said it did not recommend enforcement action, that only shows a phase of compliance risk has eased. It does not prove that this growth path has no social controversy.

  More importantly, the FDA is promoting NAMs: in vitro human-based systems, computational models, organ chips, and other methods to reduce or replace animal testing; the FDA describes NAMs as a regulatory science transformation to reduce, replace, or refine animal testing, and the roadmap also sets a long-term goal of making animal studies the exception rather than the routine in some non-clinical safety settings. Therefore, CRL's sustainable growth cannot be built on “more animals, more NHPs, and more profit from tighter supply.” That path is neither clean enough nor long enough at the regulatory and social levels.

  The healthier path is for CRL to rebuild itself from a traditional animal testing platform into a platform for “non-clinical execution + NAMs validation + regulatory understanding + multi-method integration.” The problem is that this transition has not yet been proven by financial results: in Q1 2026, RMS organic revenue was -5.5%, DSA organic revenue was -1.4%, and full-year organic revenue guidance remained (1.5)% to (0.5)%. So my answer to Question 7 leans cautious: customers would miss it, but social and regulatory sustainability only earns a “conditional pass.” If CRL transforms along NAMs and the 3R principle, it may still be an important platform; if long-term growth still mainly depends on bottlenecks in animal/NHP supply, that is not the sustainable growth model a high-quality growth stock should have.

  Jun 6, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or deteriorate with scale? Where does the money it earns go?4/10

  A

  Conclusion: CRL's unit economics are “core DSA still profitable, cash flow strong, but not an increasingly asset-light compounding machine.” Based on company segment disclosures, DSA 2025 revenue was $2.403 billion, cost of revenue was $1.686 billion, and operating income was $425 million, implying roughly $717 million of gross profit, a gross margin of about 29.8%, and segment operating margin of about 17.7%. This margin is not bad, but it is already below DSA's 2023 segment operating margin of about 23.2%, showing that scale advantages and operating leverage exist, but once utilization, research model costs, and the pace of study starts change, profit is meaningfully eaten away.

  Does the business get better as scale increases? The answer is: it improves when demand is full and capacity utilization is high; it deteriorates when customers are cautious, NHP/large-model costs rise, and sites are being consolidated. Q1 2026 was the negative example: DSA organic revenue declined 1.4%, non-GAAP operating margin fell from 23.9% in the prior-year period to 21.0%, and the company explained that direct costs related to large-model sourcing and study starts were higher. This shows CRL is not software where selling one more copy has almost zero marginal cost. It is a heavy-operations business driven jointly by scientific staff, GLP facilities, animal models, supply chains, and regulatory quality systems.

  Cash flow looks much better than the income statement. In 2025, the company had a GAAP net loss of about $142 million, but operating cash flow was $738 million and capital expenditure was $219 million, resulting in free cash flow of about $518 million; the report's conservative estimate of owner earnings is about $520-560 million. The key point here is that cash generation has not collapsed, but capex is not optional. In 2025, DSA's own capex was about $133 million, around 60% of total company capex, showing that the core profit pool still requires continued investment in facilities, model supply, and laboratory infrastructure.

  The real deduction is the credibility of incremental returns. In 2024-2025, the income statement showed a lot of recognition that “past investments performed worse than expected”: 2025 Manufacturing goodwill impairment was $165 million, and 2024 goodwill impairment in the same direction was $215 million; at the same time, 2025 also saw intangible asset impairments related to RMS's Cell Solutions and Manufacturing's CDMO assets. These impairments do not directly consume current-period cash, but they show that some money invested in Biologics, CDMO, Cell Solutions, and related directions did not generate the originally expected economic return.

  The money earned mainly goes to four places: first, capex required to maintain and expand the business; second, buybacks; third, M&A and supply-chain vertical integration; fourth, debt repayment and refinancing. In 2025, the company repurchased 2.1 million shares and spent $350 million, equivalent to most of that year's free cash flow; in Q1 2026, it again repurchased 1.1 million shares, spent $200 million, and had $800 million of authorization remaining. These buybacks are not unreasonable, but at a share price around $180 and while the company is still in transition, they also cannot be called clearly high-return capital allocation.

  Debt and M&A make this business more “hard asset” in character. At the end of 2025, the company had total debt and finance leases of $2.152 billion; by Q1 2026, long-term debt, net and finance leases rose to $2.663 billion, with one major backdrop being the company's $510 million acquisition of Cambodian NHP supplier K.F. Cambodia, bringing key supply-chain risk onto the balance sheet. At the same time, in 2026 the company completed the CDMO and Cell Solutions divestitures and planned to sell certain European Discovery Services sites. This in-and-out shows management is shrinking lower-quality assets and strengthening the core DSA supply chain, but it also shows CRL's growth is not low-capital natural expansion. It requires repeated portfolio surgery.

  So the answer to Question 8 is neutral to cautious: CRL's core unit economics still work, and DSA is a good business that can produce profit and cash; but scale advantages do not automatically bring ever-higher incremental returns. It will only become a “bigger is better” business again if core DSA/RMS demand recovers, NHP costs are controlled, the post-divestiture asset base is more focused, and buybacks do not crowd out necessary reinvestment. Otherwise, the cash earned will continue to be divided among capex, supply-chain M&A, post-impairment restructuring, debt, and buybacks. Shareholders get a heavy-asset platform with decent cash flow, but not much room for capital-allocation error.

  Jun 6, 2026
• QWhat conditions must all be true for it to rise fivefold over ten years? Are those conditions realistic? What expectations are embedded in today's stock price?3/10

  A

  Conclusion: A fivefold rise in CRL over ten years is not completely impossible, but it requires “reaccelerating revenue, a material step-up in cash margins, a NAMs transition that does not damage the core business, and valuation rerating” to happen at the same time. At today's roughly $181 share price and roughly $8.7 billion market value, the market is embedding neutral repair, not a Baillie Gifford-style fivefold growth stock.

  As of the U.S. market close on 2026-06-05, CRL's share price was about $181.34 and market value was about $8.73 billion; a fivefold market value would be about $43 billion. The local report's conservative owner earnings estimate is $520-560 million, meaning today's valuation is roughly 15.5-16.8 times owner earnings, broadly consistent with StockAnalysis's market value and closing price data.

  The core math to reach $43 billion in ten years is:

  Multiple the market is willing to pay in ten years	Required owner earnings / cash profit	Relative to today's $520-560 million	Ten-year compound growth rate
  20x	about $2.15 billion	about 3.8-4.1 times	about 14-15%
  25x	about $1.72 billion	about 3.1-3.3 times	about 12-13%

  This already shows the difficulty: CRL is not an asset-light software company, but a non-clinical R&D outsourcing platform that continuously invests in facilities, scientific personnel, research models, compliance systems, and capex. In 2025, the company had operating cash flow of about $737.6 million, capex of about $219.2 million, and reported free cash flow of about $518 million; these cash flows are real, but they also show the current cash profit pool is still far from $1.7-2.2 billion, and the cash flow data disclosed in the company's 2025 10-K support this point.

  For a ten-year fivefold outcome, at least four conditions must be met at the same time:

  1. Revenue must move from the $4 billion level toward the $8-10 billion level.
     If owner earnings margin reaches 22% in ten years, the 25x scenario requires about $7.8 billion of revenue and the 20x scenario requires about $9.8 billion of revenue; if cash margin is only 18%, they require about $9.6 billion and $11.9 billion of revenue respectively. In other words, CRL needs to sustainably recover to mid-to-high-single-digit or even low-double-digit revenue CAGR, not just deliver one or two years of cyclical rebound.

  2. Cash margins must structurally improve.
     Current owner earnings of $520-560 million against 2025 revenue of $4.015 billion imply a cash margin of about 13-14%. A fivefold scenario usually requires this to rise to 18-22% or higher, and it cannot “squeeze” cash flow by cutting necessary capex. This requires DSA margins to recover, site consolidation to work, the post-CDMO/Cell Solutions portfolio to be cleaner, and NHP costs, legal matters, and restructuring costs to stop repeatedly consuming profit.

  3. NAMs must not pierce the old moat; instead, CRL must become the validation/integration platform for new methods.
     The FDA is promoting NAMs, AI, organ-on-chip, in vitro, and other methods to reduce or replace animal testing. The FDA NAMs page clearly frames the direction as reducing, replacing, or refining animal experiments. For CRL, this is both the biggest risk and the second curve that must work in a fivefold story: if it is merely a traditional animal/NHP testing platform, it will be hard for the valuation to rise to 25x; if it can become critical infrastructure for “traditional non-clinical + NAMs + regulatory validation,” it has room for rerating.

  4. Capital allocation cannot make major mistakes again.
     Past impairments and asset divestitures show that some acquisition quality was average. A ten-year fivefold outcome requires future cash to mainly flow toward high-return reinvestment, buybacks when undervalued, and deleveraging, rather than continuing to buy growth through M&A and then write it off through impairments. The company was still buying back shares in Q1 2026 and completed the CDMO and Cell Solutions divestitures; the Q1 2026 announcement also showed 2026 organic revenue guidance of -1.5% to -0.5% and non-GAAP EPS guidance of $10.80-11.30. This shows the “repair” is still early and has not proven a move into a long-term high-growth trajectory.

  In terms of realism, I would classify this as a low-probability but trackable upside scenario, not the base case. CRL has scale, customer diversification, regulatory experience, and a cash-flow base, and DSA remains a valuable core asset; but the company's own 2026 organic growth guidance is still negative, and RMS and DSA organic revenue were still declining in Q1. Moving from this starting point to 12-15% owner earnings CAGR over ten years requires more than demand recovery. It requires a step-up in the quality of the business model.

  The expectations embedded in today's stock price look more like this: the market believes CRL will not structurally collapse, cash flow can be maintained, margins will gradually recover after divestitures, and organic growth will return to low-single-digit positive territory; but the market is not yet pricing in “12-15% compound cash-profit growth over ten years + a 20-25x terminal valuation.” If the market already believed this fivefold story, it would not value the company at only about 16 times owner earnings today. Conversely, today's price is not extremely pessimistic either: it already requires the company to defend the $520-560 million owner earnings cash floor and gradually prove that the 2026-2027 operating recovery is real.

  Jun 6, 2026
• QWhy has the market not recognized all this yet? Is it failing to understand, looking down on it, or not looking far enough? What will become the “narrative inflection point”?3/10

  A

  Conclusion: The market has not completely missed CRL's cash flow; it is unwilling to translate “cash flow remains strong” directly into “long-term compounding remains strong.” This is not a typical “the market does not understand” story. It is more that the market understands 2025 operating cash flow of about $738 million and free cash flow of about $518 million, and also understands that the current share price of about $180-181 and market value of about $8.7 billion are not absurdly expensive; but at the same time, the market is discounting regulatory migration, weak demand, impairments, M&A quality, and questions around the NHP supply chain. As of the close on June 5, 2026, CRL's share price was $181.34 and market value was about $8.73 billion, and this pricing looks more like a neutral valuation waiting for evidence than “an undiscovered deep bargain.”

  It is not failing to understand. CRL's core business is not mysterious: in its 2025 10-K, the company itself says it is a leading global non-clinical drug development partner, with DSA providing drug discovery, non-clinical development, and regulated safety assessment, and with 2025 DSA revenue of $2.403 billion, about 59.8% of total revenue of $4.015 billion. The customer base is also sufficiently diversified: in 2025, no single customer accounted for more than 4% of total revenue, and no single customer accounted for more than 8% of any segment's revenue. The market can understand that this is a CRO platform with scale, compliance barriers, customer trust, and cash-flow inertia.

  It is also not simply looking down on it. The market is not pricing CRL as a bankruptcy or secular-decline asset: based on the company's 2026 non-GAAP EPS guidance of $10.80-11.30, the current valuation is about 16 times forward non-GAAP PE; based on this report's estimated $520-560 million of owner earnings, it is also not a neglected cigar-butt price. The real issue is that the market sees this cash flow as “sustainable but needing proof again,” rather than “naturally able to compound for a long time.”

  The first layer of discount is that demand has not returned to growth. In Q1 2026, CRL disclosed that RMS organic revenue declined 5.5%, DSA organic revenue declined 1.4%, and full-year organic revenue guidance remained -1.5% to -0.5%; at the same time, DSA non-GAAP operating margin fell from 23.9% in the prior-year period to 21.0%. These numbers show that cautious customer budgets, the pace of project starts, and site consolidation are still weighing on the business, and the operating inflection point has not yet been confirmed by financial results.

  The second layer of discount is that the regulatory paradigm is migrating. The FDA is promoting NAMs, using in vitro, human-based, computational, AI, organ-chip, and other methods to reduce or replace some animal testing; the FDA page explicitly describes this as a transformation to reduce, replace, or refine animal testing, and continues to advance the related framework in 2026. This is a double-edged sword for CRL: if it is only a traditional animal/NHP testing platform, the valuation should be compressed; if it can become the platform for NAMs validation, integration, and regulated delivery, the market may be underestimating the second curve today. The problem is that the latter still needs commercialization evidence.

  The third layer of discount is M&A and portfolio quality. In 2024-2025, GAAP earnings were heavily dragged down by goodwill, intangible asset, and held-for-sale asset impairments, and in Q1 2026 the company also recognized a $118 million loss related to the CDMO and Cell Solutions divestiture. The market is not ignoring free cash flow. It is asking how much of that cash flow comes from a genuinely high-quality, compounding core business, and how much is merely a repair-period benefit after divesting past M&A mistakes.

  So if forced to choose among “not understanding, looking down on it, or not looking far enough,” my answer is: the market understands it and is not completely looking down on it, but for now it is unwilling to look too far ahead. It is asking CRL to first prove that it is not a “company in the old animal-testing value chain being slowly discounted by regulation,” but a “platform that can continue taking key budgets in the new non-clinical evaluation system.”

  The real narrative inflection point will not be a press conference, but evidence over several consecutive quarters:

  • DSA organic revenue turns positive: not from FX, acquisitions, or one-off projects, but from renewed positive growth in core safety assessment and discovery services.
  • Margin recovery: DSA non-GAAP margin moves back from around 21% to a healthier range, and not through short-term improvement achieved by cutting long-term capabilities.
  • NAMs commercialization: the company can provide quantifiable revenue, customer adoption cases, and evidence of use in regulatory submissions, proving that it is an integrator of NAMs rather than a party being replaced by NAMs.
  • NHP risk under control: supply chain, compliance, inventory, legal costs, and integration of the Cambodian NHP assets stop repeatedly creating cost shocks.
  • Clean post-divestiture portfolio: after CDMO, Cell Solutions, and certain European Discovery Services sites are dealt with, large impairments stop recurring, allowing investors to see core CRL's true margin profile.
  • Clear buyback discipline: in Q1 2026 the company had already repurchased 1.1 million shares and spent $200 million, with $800 million of authorization remaining; the narrative inflection point requires buybacks to rest on reasonable prices, sound leverage, and disciplined M&A, instead of using financial engineering to mask insufficient growth.

  In one sentence, what the market lacks is not “discovering that CRL has cash flow,” but “believing these cash flows can cross regulatory migration and asset restructuring, then return to a compounding track.” Once the narrative shifts from “a traditional non-clinical platform discounted by NAMs and M&A aftereffects” to “a cleaner post-divestiture non-clinical infrastructure company with DSA recovery, commercializable NAMs, and disciplined capital allocation,” valuation rerating can truly begin.

  Jun 6, 2026